Next Article in Journal
The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent
Next Article in Special Issue
Personalized Piperacillin Dosing for the Critically Ill: A Retrospective Analysis of Clinical Experience with Dosing Software and Therapeutic Drug Monitoring to Optimize Antimicrobial Dosing
Previous Article in Journal
D-Penicillamine: The State of the Art in Humans and in Dogs from a Pharmacological and Regulatory Perspective
Previous Article in Special Issue
Population Pharmacokinetics and Probability of Target Attainment of Different Dosing Regimens of Ceftazidime in Critically Ill Patients with a Proven or Suspected Pseudomonas aeruginosa Infection
Correction published on 9 October 2021, see Antibiotics 2021, 10(10), 1230.
Article

Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance

1
Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
2
Department of Pharmacy, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
3
Department of Microbiology, University Medical Center Hamburg-Eppendorf, Virology and Hygiene, 20251 Hamburg, Germany
4
Department of Pharmacy, General Hospital of Heidenheim, 89522 Heidenheim, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Antonello Di Paolo
Antibiotics 2021, 10(6), 649; https://doi.org/10.3390/antibiotics10060649
Received: 27 April 2021 / Revised: 17 May 2021 / Accepted: 24 May 2021 / Published: 28 May 2021
Cefiderocol is a new siderophore-cephalosporin for the treatment of multi-drug resistant Gram-negative pathogens. As a reserve agent, it will and should be used primarily in critically ill patients in the upcoming years. Due to the novelty of the substance little data on the pharmacokinetics in critically ill patients with septic shock and renal failure (including continuous renal replacement therapy and cytokine adsorber therapy) is available. We performed therapeutic drug monitoring in a cohort of five patients treated with cefiderocol, to improve the knowledge on pharmacokinetics in this vulnerable patient population. As expected for a cephalosporin with predominantly renal elimination the maintenance dose could be reduced in patients with renal impairment or on continuous renal replacement therapy. The manufacturer’s dosing instructions were sufficient to achieve a drug level well above the MIC. However, the addition of a cytokine adsorber might reduce serum levels substantially, so that in this context therapeutic drug monitoring and dose adjustment are recommended. View Full-Text
Keywords: cefiderocol; therapeutic drug monitoring; pharmacokinetics; critically ill patients; continuous veno-venous hemodialysis cefiderocol; therapeutic drug monitoring; pharmacokinetics; critically ill patients; continuous veno-venous hemodialysis
Show Figures

Figure 1

MDPI and ACS Style

König, C.; Both, A.; Rohde, H.; Kluge, S.; Frey, O.R.; Röhr, A.C.; Wichmann, D. Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance. Antibiotics 2021, 10, 649. https://doi.org/10.3390/antibiotics10060649

AMA Style

König C, Both A, Rohde H, Kluge S, Frey OR, Röhr AC, Wichmann D. Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance. Antibiotics. 2021; 10(6):649. https://doi.org/10.3390/antibiotics10060649

Chicago/Turabian Style

König, Christina, Anna Both, Holger Rohde, Stefan Kluge, Otto R. Frey, Anka C. Röhr, and Dominic Wichmann. 2021. "Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance" Antibiotics 10, no. 6: 649. https://doi.org/10.3390/antibiotics10060649

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop